Arena Pharmaceuticals Inc (ARNA.A)

ARNA.A on American Stock Exchange

4.72USD
29 Jul 2014
Price Change (% chg)

$0.12 (+2.61%)
Prev Close
$4.60
Open
$4.65
Day's High
$4.75
Day's Low
$4.65
Volume
21,786
Avg. Vol
39,486
52-wk High
$7.96
52-wk Low
$4.05

ARNA.A

Chart for ARNA.A

About

Arena Pharmaceuticals, Inc. (Arena) is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors. Its wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize BELVIQ in the United States. The Company’s... (more)

Overall

Beta: -0.42
Market Cap (Mil.): $1,012.59
Shares Outstanding (Mil.): 219.65
Dividend: --
Yield (%): --

Financials

  ARNA.A Industry Sector
P/E (TTM): -- 103.84 36.07
EPS (TTM): -0.12 -- --
ROI: -10.12 -0.24 18.18
ROE: -25.00 -1.24 19.05
Search Stocks

MARKET PULSE-3D Systems, Medivation, Plug Power, Arena Pharma

U.S. stocks rose on Friday as some positive economic data boosted the S&P 500 to record levels for a second straight day and put major indexes on track for strong gains in both the week and the month. The Dow Jones industrial average was up 0.49 percent at 16,351.94, the S&P 500 was up 0.48 percent at 1,863.17 and the Nasdaq Composite was up 0.27 percent at 4,330.511.

28 Feb 2014

CORRECTED-BRIEF-Arena Pharmaceuticals qtrly loss per share $0.11 (Feb 27)

(Corrects second bullet in Feb 27 item to say the company expects revenue of $9 mln from amortization of collaboration payments in 2014, not total revenue. Arena did not forecast total revenue) Feb 27 - Arena Pharmaceuticals Inc : * Provides corporate update and reports fourth quarter and full year 2013 financial results * Sees FY 2014 revenue of about $9 million from amortization of upfront payments from existing collaborations * Qtrly total revenues $6.5 million versus $1.9 millio

28 Feb 2014

Competitors

  Price Change
Novo Nordisk A/S (NOVOb.CO) kr.256.50 +2.50
Roche Holding Ltd. (ROG.VX) CHF265.80 +0.30
GlaxoSmithKline plc (GSK.L) 1,419.00p +4.50
VIVUS, Inc. (VVUS.OQ) $4.85 +0.03
Orexigen Therapeutics, Inc. (OREX.OQ) $5.19 +0.06

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks